PURPOSE: Exclusion of patients needing urgent treatment or requiring novel biomarkers before enrollment has impacted the ability to enroll real-world patients in frontline trials of diffuse large B-cell lymphoma (DLBCL). The impact of baseline organ function-based eligibility criteria on this effect and clinical trial exclusion is less well-understood. METHODS: Consecutive patients with newly diagnosed lymphoma were enrolled from 2002 to 2015 into the Molecular Epidemiology Resource (MER) of the University of Iowa and Mayo Clinic Lymphoma Specialized Program of Research Excellence. The current analysis includes 1,265 patients with DLBCL receiving standard immunochemotherapy. Organ function parameters were identified from criteria for hemoglobin, absolute neutrophil count, platelet count, creatinine clearance, and bilirubin, as reported in frontline DLBCL trials. Abstracted laboratory values from MER were used to determine the percent (%) of patients excluded. Outcomes and cause-of-death analyses comparing ineligible and eligible groups in MER were conducted. An interactive online tool was developed to estimate exclusions based on organ function for future trial design. RESULTS: Between 9% and 24% of MER patients with DLBCL receiving standard immunochemotherapy were excluded on the basis of baseline organ function alone. Ineligible patients based on organ function had significantly inferior event-free survival (hazard ratios, 1.67-2.16), overall survival (hazard ratios, 1.87-2.56), and event-free survival at 24 months (odds ratio, 1.71-2.16). Ineligible patients were more likely to die from lymphoma progression than increased therapy-related complications. CONCLUSION: Current national and international trials exclude up to 24% of patients from participation on the basis of organ function alone. A significant difference in the outcomes, notably lymphoma-related death, suggests issues with generalization and potential exclusion of high-risk patients. These data will help future clinical trial development and meet US Food and Drug Administration and ASCO recommendations to increase trial accrual.
PURPOSE: Exclusion of patients needing urgent treatment or requiring novel biomarkers before enrollment has impacted the ability to enroll real-world patients in frontline trials of diffuse large B-cell lymphoma (DLBCL). The impact of baseline organ function-based eligibility criteria on this effect and clinical trial exclusion is less well-understood. METHODS: Consecutive patients with newly diagnosed lymphoma were enrolled from 2002 to 2015 into the Molecular Epidemiology Resource (MER) of the University of Iowa and Mayo Clinic Lymphoma Specialized Program of Research Excellence. The current analysis includes 1,265 patients with DLBCL receiving standard immunochemotherapy. Organ function parameters were identified from criteria for hemoglobin, absolute neutrophil count, platelet count, creatinine clearance, and bilirubin, as reported in frontline DLBCL trials. Abstracted laboratory values from MER were used to determine the percent (%) of patients excluded. Outcomes and cause-of-death analyses comparing ineligible and eligible groups in MER were conducted. An interactive online tool was developed to estimate exclusions based on organ function for future trial design. RESULTS: Between 9% and 24% of MER patients with DLBCL receiving standard immunochemotherapy were excluded on the basis of baseline organ function alone. Ineligible patients based on organ function had significantly inferior event-free survival (hazard ratios, 1.67-2.16), overall survival (hazard ratios, 1.87-2.56), and event-free survival at 24 months (odds ratio, 1.71-2.16). Ineligible patients were more likely to die from lymphoma progression than increased therapy-related complications. CONCLUSION: Current national and international trials exclude up to 24% of patients from participation on the basis of organ function alone. A significant difference in the outcomes, notably lymphoma-related death, suggests issues with generalization and potential exclusion of high-risk patients. These data will help future clinical trial development and meet US Food and Drug Administration and ASCO recommendations to increase trial accrual.
Authors: Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544
Authors: Kah Poh Loh; Andrea Baran; Christina Y Lee; Alfadel Alshaibani; Sarah C Rutherford; John Hu; Carla Casulo; Paul M Barr; Jonathan W Friedberg; Patrick M Reagan Journal: Leuk Lymphoma Date: 2019-07-08
Authors: Grzegorz S Nowakowski; Jun Zhu; Qingyuan Zhang; Joshua Brody; Xiuhua Sun; Joseph Maly; Yuqin Song; Syed Rizvi; Yongping Song; Frederick Lansigan; Hongmei Jing; Junning Cao; Jennifer K Lue; Wen Luo; Lei Zhang; Ling Li; Isabel Han; Joan Sun; Manoj Jivani; Young Liu; Thomas Heineman; Stephen D Smith Journal: Future Oncol Date: 2020-04-06 Impact factor: 3.404
Authors: Umberto Vitolo; Marek Trněný; David Belada; John M Burke; Angelo Michele Carella; Neil Chua; Pau Abrisqueta; Judit Demeter; Ian Flinn; Xiaonan Hong; Won Seog Kim; Antonio Pinto; Yuan-Kai Shi; Yoichi Tatsumi; Mikkel Z Oestergaard; Michael Wenger; Günter Fingerle-Rowson; Olivier Catalani; Tina Nielsen; Maurizio Martelli; Laurie H Sehn Journal: J Clin Oncol Date: 2017-08-10 Impact factor: 44.544
Authors: Joseph M Unger; William E Barlow; Diane P Martin; Scott D Ramsey; Michael Leblanc; Ruth Etzioni; Dawn L Hershman Journal: J Natl Cancer Inst Date: 2014-03-13 Impact factor: 13.506
Authors: Juan C Ramos; Joseph A Sparano; Amy Chadburn; Erin G Reid; Richard F Ambinder; Eric R Siegel; Page C Moore; Paul G Rubinstein; Christine M Durand; Ethel Cesarman; David Aboulafia; Robert Baiocchi; Lee Ratner; Lawrence Kaplan; Adam A Capoferri; Jeannette Y Lee; Ronald Mitsuyasu; Ariela Noy Journal: Blood Date: 2020-09-10 Impact factor: 25.476
Authors: Grzegorz S Nowakowski; Annalisa Chiappella; Thomas E Witzig; Michele Spina; Randy D Gascoyne; Lei Zhang; Jocelyne Flament; Jacqueline Repici; Umberto Vitolo Journal: Future Oncol Date: 2016-04-18 Impact factor: 3.404
Authors: Andrew Davies; Thomas E Cummin; Sharon Barrans; Tom Maishman; Christoph Mamot; Urban Novak; Josh Caddy; Louise Stanton; Shamim Kazmi-Stokes; Andrew McMillan; Paul Fields; Christopher Pocock; Graham P Collins; Richard Stephens; Francesco Cucco; Alexandra Clipson; Chulin Sha; Reuben Tooze; Matthew A Care; Gareth Griffiths; Ming-Qing Du; David R Westhead; Catherine Burton; Peter W M Johnson Journal: Lancet Oncol Date: 2019-04-01 Impact factor: 41.316